Teva autoimmune news

The U.S. Supreme Court denied a motion from Teva to stay an appeals court ruling that will end exclusivity for the biotech's Copaxone glatiramer acetate to treat multiple sclerosis (MS) on May 24. Teva was seeking the stay pending its appeal of the appeals court ruling. The Supreme Court agreed to hear the appeal last month, but in his denial of the stay, Chief Justice John Roberts said Teva failed to show a "likelihood of irreparable harm resulting from denial of a stay" because the company will be able to recover damages if it prevails (see BioCentury, April 7). ...